Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott

Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet